Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
Sanofi has simplified its contractual agreements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.). Under the new and updated arrangements, Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the U.S. […]
Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements Read More »